Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-914143 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2) | EXPERIMENTAL | BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2 |
| Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2) | EXPERIMENTAL | BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2 |
| Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2) | EXPERIMENTAL | BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2 |
| Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2) | EXPERIMENTAL | BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2 |
| Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2) | EXPERIMENTAL | BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR \< 15 mL/min/1.73 m2 (on hemodialysis \[HD\] or non-HD) |
| Name | Type | Description |
|---|---|---|
| BMS-914143 (Peginterferon Lambda-1a) | BIOLOGICAL | - |
Inclusion Criteria: * Normal renal function or mild, moderate, severe or end-stage renal dysfunction Exclusion Criteria: * History of uncontrolled or unstable cardiovascular, respiratory, gastrointestinal, hepatic, endocrine, hematopoietic, psychiatric or neurological conditions within 6 months o...
BMS-914143 is a monoclonal antibody being developed by Bristol-Myers Squibb for the treatment of chronic Hepatitis B virus infection. It is currently in Phase 1 clinical development as an investigational therapy for this infectious disease indication.
BMS-914143 is a monoclonal antibody, but its specific molecular target has not been disclosed in available clinical trial information. The drug is being studied for its potential role in treating chronic Hepatitis B virus infection.
BMS-914143 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research on this investigational monoclonal antibody.
BMS-914143 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 study has been completed, and the drug remains in early-stage clinical testing for chronic Hepatitis B virus infection.
BMS-914143 has one completed clinical trial, NCT01708889, a pharmacokinetic study in participants with normal renal function and various degrees of renal dysfunction. The study enrolled 43 participants and included patients with chronic Hepatitis B or C virus infection, as well as healthy volunteers.
BMS-914143 is the investigational name used by Bristol-Myers Squibb for this monoclonal antibody. No alternative names have been reported in the available clinical trial information for this drug candidate.